Nutrien Increases Quarterly Dividend and Announces Intent to Launch a New Share Repurchase Program Phosphate Investing
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON Injection from U.S. Centers for Medicare & Medicaid Services Phosphate Investing
Spectrum Pharmaceuticals Provides Update on ROLVEDON Injection and Announces Unaudited Fourth Quarter 2022 Financial Results Phosphate Investing
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff Phosphate Investing
Agriculture Market Forecast: Top Trends That Will Affect Potash and Phosphate in 2023 Agriculture Investing
Nutrien Announces Release Dates for Fourth Quarter 2022 Results and Conference Call Phosphate Investing
Spectrum Pharmaceuticals' ROLVEDON Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors Phosphate Investing
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff Phosphate Investing
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON injection Phosphate Investing
